Patents by Inventor Chandu B. Patel

Chandu B. Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof
    Patent number: 7824908
    Abstract: The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii. Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination.
    Type: Grant
    Filed: September 24, 2007
    Date of Patent: November 2, 2010
    Inventors: Gregory T. Maine, Chandu B. Patel, Sanford R. Ginsburg, Timothy R. Bliese
  • GENETICALLY ENGINEERED P30 ANTIGEN, IMPROVED ANTIGEN COCKTAIL, AND USES THEREOF
    Publication number: 20080160606
    Abstract: The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii. Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination.
    Type: Application
    Filed: September 24, 2007
    Publication date: July 3, 2008
    Inventors: Gregory T. Maine, Chandu B. Patel, Sanford R. Ginsburg, Timothy R. Bliese
  • Polynucleotide encoding a genetically engineered P30 antigen
    Patent number: 7314924
    Abstract: The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii. Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: January 1, 2008
    Assignee: Abbott Laboratories
    Inventors: Gregory T. Maine, Chandu B. Patel, Sanford R. Ginsburg, Timothy R. Bliese
  • Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof
    Patent number: 7094879
    Abstract: The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii. Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: August 22, 2006
    Assignee: Abbott Laboratories
    Inventors: Gregory T. Maine, Chandu B. Patel, Sanford R. Ginsburg, Timothy R. Bliese
  • Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof
    Publication number: 20040067239
    Abstract: The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii. Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination.
    Type: Application
    Filed: October 2, 2002
    Publication date: April 8, 2004
    Inventors: Gregory T. Maine, Chandu B. Patel, Sanford R. Ginsburg, Timothy R. Bliese
  • One-step competitive immunoassay for the semiquantitative determination of plasma lipoprotein(a)
    Patent number: 5229073
    Abstract: A competitive immunoassay to measure Lp(a) levels semiquantitatively and identify individuals with elevated plasma Lp(a) protein levels (greater than 7 mg/dl) who have an increase risk for coronary artery disease. The assay is useful for monitoring the effectiveness of Lp(a)-lowering drugs. The assay provides a quick, reliable, easy to use and inexpensive method to measure plasma Lp(a) level with serum, plasma or whole blood.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: July 20, 1993
    Assignee: Abbott Laboratories
    Inventors: Sheng-Chang Luo, Chandu B. Patel